Vitamin B3 Shows Promise in Tackling Fatty Liver Disease

Metabolic-associated fatty liver disease (MASLD), affecting nearly one-third of the global population, has long lacked targeted treatments. New research now highlights a genetic driver behind the condition and points to a surprising solution — vitamin B3.

An international team of scientists identified microRNA-93 (miR-93) as a key molecule influencing disease progression. Elevated levels of miR-93 were found to disrupt liver function by blocking SIRT1, a gene essential for regulating fat metabolism. This disruption leads to increased fat accumulation, inflammation, and liver damage.

In experimental studies, suppressing miR-93 improved liver health and insulin response, while higher levels worsened metabolic outcomes. Researchers then screened existing drugs and found that niacin (vitamin B3) effectively reduced miR-93 levels and restored normal metabolic processes.

Given its established safety profile, vitamin B3 could emerge as a promising therapeutic option, potentially paving the way for new combination treatments for MASLD.

29-03-2026